Search 

Xuanzhu Biopharmaceutical was founded in 2002. In 2012, it became a wholly-owned subsidiary of Sihuan Pharmaceutical. In 2018, Xuanzhu Biopharmaceutical spun-off and became independent, with a registered capital of RMB1.15 billion. Different from other emerging unprofitable biotechnology companies, Xuanzhu Biopharmaceutical is one of the few domestic innovative drug companies with a complete research and development industry chain. It has not only more than a dozen innovative R&D products, but also support from a leading domestic pharmaceutical company in Sihuan Pharmaceutical. With strong production and commercialization capabilities, Xuanzhu Biopharmaceutical possesses the potential of becoming an international enterprise integrating R&D, manufactuing and marketing platforms.

healthcare VC

Leading life science venture capital firm investing in pre-clinical or early clinical stage.

Project assessment, auditing, project management, regulatory affairs, quality, and IP management services

2nd market PE,
about 300M RMB total value,
mainly focus on A-share market and startup on H-share market,
concentrating on high-speed developing industrials especially in Healthcare, including Big Biopharma/Superior Biotech companies.

ZY Therapeutics Inc. is a venture backed startup company focusing on developing innovative precision drug delivery technology. It was founded by two scientists in 2015 in North Carolina. In 2017, ZY’s leading project won collaboration award from Nanotechnology Characterization Lab (NCL), part of national lab established by FDA, NCI and NIST in a concerted effort to regulate and support nanotechnology in oncology space. ZY’s proprietary delivery platforms currently focus on optimized injectable formulations to deliver oncology therapy to the action sites. The first biodegradable oncology nano-formulation, ZY-010-PNP, completed Pre-IND discussion with the FDA and agreement on 505b(2) regulatory pathway was achieved. Further, the isotope labeling human plasma In vitro study as well as canine pharmacokinetic study conducted by NCL suggest a unique drug releasing profile in comparison to the benchmark brands suggesting enhanced the therapeutic effect with lower safety concern. An IND was filed with favorable responses of communication from FDA were received in 2018 and 2020. The active targeting delivery nanomedicine ZY-012-CNP for prostate cancer is in preclinic development and scheduled to file Pre-IND application in Q2 2021. Additional products are in encapsulation feasibility studies. The target indications cover majority of solid tumors, including but not limited to TNBC, Ovarian Cancer and mCPRC, of which xenograft in vivo models have proved the drug efficacy. On the same platform, additional active drugs with solubility and / or acute toxicity issues were successfully formulated to greatly improve delivery efficacy and safety.
ZY has developed multiple platform technologies and related patents were filed to protect global rights. Additional patents on individual product will be filed to protect the exclusive rights. This layered IP strategy ensures a long patent life for future product.
Located in Research Triangle Park in North Carolina, ZY Therapeutics has an interdisciplinary R&D team and 4,500+ sf lab space right in the heart of the southeast bio-hub. Co-founder and CEO Dr. Jian Bao has 20 years’ experience in pharmaceutical development, from discovery to clinical development. She received PhD from University of Pittsburgh and B.S. from Beijing University, both in Chemistry. Co-founder and CSO Dr. Jun Li has many years of experience in innovative drug delivery system. The core team has a combined decades of pharmaceutical product development experience, with veteran cross-functional team leaders. ZY has assembled an advisor board that consists of world class experts in drug delivery and oncologists from both academia and industry.
ZY Therapeutics is actively seeking funding and collaboration to further develop our platform technologies and promising candidates. We look forward to taking our nano-formulations to clinic in 2021 and beyond.

创新性药物开发公司；已有多个仿制药和创新药上市；丰富的在研产品线；母公司已有两家上市公司，准备第3家公司上市；

为终端医疗机构提供创新共赢的治疗解决方案
与推动行业发展的合作伙伴一道,整合医疗行业资源,探索创新业务体系,为终端医疗机构提供创新共赢的治疗解决方案辅助客户优化内部结构和管理,更好的服务于医疗终端和广大患者……
产品：血管外科腔内治疗“精准治疗辅助系统、放疗科癌症后装放疗“精准放疗辅助系统。

北京，2015年成立，2020年港股上市，临床阶段

纳米抗体研发,肿瘤免疫治疗